Pharmamarketeer
overig

BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression

9 februari 2018
Pharmafile

Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) in patients whose cancers have a high tumour mutation burden (TMB), regardless of PD-L1 expression.

Reageer

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)